DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern.
- Ongoing emphasis on growing revenue for the DermTech Melanoma Test
- Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring.
DermTech (DMTK) Reports Positive Topline Results From a Study Evaluating the DermTech Melanoma Test Across All Skin Types streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- Trust 2 Study confirms negative predictive value of 99.7% for the foundational gene expression assay
- Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or.